Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis

Overview

Journal J Neurogastroenterol Motil

Date 2024 Jan 4

PMID 38173154

Authors

Will Takakura

Ali Rezaie

William D Chey

Jiajing Wang

Mark Pimentel

Affiliations

Soon will be listed here.

Abstract

Background/aims: We performed a systematic review and meta-analysis evaluating the symptomatic response rate to antibiotics in patients with small intestinal bacterial overgrowth (SIBO). Similarly, we performed a meta-analysis on the symptomatic response to antibiotics in irritable bowel syndrome (IBS) patients with and without SIBO.

Methods: MEDLINE, EMBASE, Web of Science, and Cochrane databases were searched from inception to March 2021. Randomized controlled trials and prospective studies reporting dichotomous outcomes were included.

Results: There were 6 studies included in the first meta-analysis comparing the efficacy of antibiotics to placebo or no antibiotic. This included 196 patients, of whom 101 received antibiotics and 95 received placebo or no antibiotics. Significantly more patients improved with antibiotics (relative risk [95% CI] = 2.46 [1.33-4.55], = 0.004). There were 4 studies included in the analysis comparing symptomatic response rates in IBS patients with or without SIBO with 266 IBS patients, of whom 172 had SIBO and 94 did not. The pooled response rate for symptomatic response was 51.2% in the SIBO group vs 23.4% in the no SIBO group, respectively. Significantly more IBS patients with SIBO responded to antibiotics compared to those without SIBO (relative risk [95% CI] = 2.07 [1.40-3.08], = 0.0003).

Conclusions: Antibiotics appear to be efficacious in treating SIBO, although small sample sizes and poor data quality limit this interpretation. Symptomatic response rates also appear to be higher in IBS patients with SIBO. This may be the first example of precision medicine in IBS as opposed to our current empiric treatment approach. Large-multicenter studies are needed to verify the results.

Citing Articles

[Small intestine bacterial overgrowth: Myths and realities].

Guardiola-Arevalo A, Mascort Roca J, Noguerol Alvarez M, Carrillo Munoz R, Mendive Arbeloa J, Amador Romero J Aten Primaria. 2025; 57(4):103201.

PMID: 39799751 PMC: 11770485. DOI: 10.1016/j.aprim.2024.103201.

Rifaximin-Alpha Increases Lactase Activity in Patients with Irritable Bowel Syndrome Without Constipation and Small Intestinal Bacterial Overgrowth.

Garcia-Cedillo M, Villegas-Garcia F, Arenas-Martinez J, Ornelas-Arroyo V, Yamamoto-Furusho J, Estrella-Sato L Dig Dis Sci. 2024; 70(1):360-366.

PMID: 39641896 DOI: 10.1007/s10620-024-08767-1.

Elemental Diet as a Therapeutic Modality: A Comprehensive Review.

Nasser J, Mehravar S, Pimentel M, Lim J, Mathur R, Boustany A Dig Dis Sci. 2024; 69(9):3344-3360.

PMID: 39001958 PMC: 11415405. DOI: 10.1007/s10620-024-08543-1.

References

Tornblom H, Lindberg G, Nyberg B, Veress B . Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002; 123(6):1972-9. DOI: 10.1053/gast.2002.37059. View

Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A . The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2018; 54(3):261-270. DOI: 10.1007/s00535-018-1509-4. View

Zhuang X, Tian Z, Luo M, Xiong L . Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2020; 20(1):187. PMC: 7291629. DOI: 10.1186/s12876-020-01336-6. View

Pimentel M, Morales W, Pokkunuri V, Brikos C, Kim S, Kim S . Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model. Dig Dis Sci. 2014; 60(5):1195-205. DOI: 10.1007/s10620-014-3435-5. View

Lembo A, Pimentel M, Rao S, Schoenfeld P, Cash B, Weinstock L . Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016; 151(6):1113-1121. DOI: 10.1053/j.gastro.2016.08.003. View

Takakura W, Pimentel M . Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry. 2020; 11:664. PMC: 7366247. DOI: 10.3389/fpsyt.2020.00664. View

Greenwood-Van Meerveld B, Johnson A . Mechanisms of Stress-induced Visceral Pain. J Neurogastroenterol Motil. 2018; 24(1):7-18. PMC: 5753899. DOI: 10.5056/jnm17137. View

Pimentel M, Saad R, Long M, Rao S . ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020; 115(2):165-178. DOI: 10.14309/ajg.0000000000000501. View

Baker J, Chey W, Watts L, Armstrong M, Collins K, Lee A . How the North American Consensus Protocol Affects the Performance of Glucose Breath Testing for Bacterial Overgrowth Versus a Traditional Method. Am J Gastroenterol. 2021; 116(4):780-787. DOI: 10.14309/ajg.0000000000001110. View

10.

Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S . Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017; 112(5):775-784. PMC: 5418558. DOI: 10.1038/ajg.2017.46. View

11.

Pimentel M, Chow E, Lin H . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003; 98(2):412-9. DOI: 10.1111/j.1572-0241.2003.07234.x. View

12.

DInca R, Pomerri F, Vettorato M, Dal Pont E, Di Leo V, Ferronato A . Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007; 25(7):771-9. DOI: 10.1111/j.1365-2036.2007.03266.x. View

13.

Rezaie A, Heimanson Z, McCallum R, Pimentel M . Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Am J Gastroenterol. 2019; 114(12):1886-1893. PMC: 6903366. DOI: 10.14309/ajg.0000000000000444. View

14.

Pimentel M, Lembo A, Chey W, Zakko S, Ringel Y, Yu J . Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364(1):22-32. DOI: 10.1056/NEJMoa1004409. View

15.

Xu D, Gao J, Gillilland 3rd M, Wu X, Song I, Kao J . Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2013; 146(2):484-96.e4. PMC: 3939606. DOI: 10.1053/j.gastro.2013.10.026. View

16.

Ghoshal U, Srivastava D, Misra A, Ghoshal U . A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016; 28(3):281-9. DOI: 10.1097/MEG.0000000000000557. View

17.

McInnes M, Moher D, Thombs B, McGrath T, Bossuyt P, Clifford T . Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018; 319(4):388-396. DOI: 10.1001/jama.2017.19163. View

18.

Shah S, Day L, Somsouk M, Sewell J . Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013; 38(8):925-34. PMC: 3819138. DOI: 10.1111/apt.12479. View

19.

Azpiroz F, Bouin M, Camilleri M, Mayer E, Poitras P, Serra J . Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007; 19(1 Suppl):62-88. DOI: 10.1111/j.1365-2982.2006.00875.x. View

20.

Cangemi D, Lacy B, Wise J . Diagnosing Small Intestinal Bacterial Overgrowth: A Comparison of Lactulose Breath Tests to Small Bowel Aspirates. Dig Dis Sci. 2020; 66(6):2042-2050. DOI: 10.1007/s10620-020-06484-z. View